دورية أكاديمية
The efficacy and safety of second salvage autologous transplantation in myeloma patients
| العنوان: | The efficacy and safety of second salvage autologous transplantation in myeloma patients |
|---|---|
| المؤلفون: | Reka Rahel Bicsko, Renata Nyilas, Robert Szasz, Laszlo Varoczy, Attila Kiss, Miklos Udvardy, Arpad Illes, Lajos Gergely |
| المصدر: | Pathology and Oncology Research, Vol 30 (2024) |
| بيانات النشر: | Frontiers Media S.A., 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens LCC:Pathology |
| مصطلحات موضوعية: | multiple myeloma, salvage therapy, salvage transplantation, second autologous stem cell transplantation, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Pathology, RB1-214 |
| الوصف: | Despite the availability of many novel therapies for multiple myeloma, it remains an incurable disease with relapse fated in almost all patients. In the era of modern agents, second autologous stem cell transplantation still holds its role in patients relapsing after first-line autologous transplant. The authors reviewed a single-center experience with a second auto-SCT for relapsed multiple myeloma. Thirty patients had received a salvage auto-SCT at the institution. The median follow-up after diagnosis was 86 months, and the median time between transplants was 59.1 months. Response before second ASCT was the following: CR – 11 cases, VGPR – 9 cases, PR – 10 cases. Most patients received reduced dose (140 mg/m2) of melphalan as a conditioning regimen for the second auto-SCT. Treatment-related mortality was 3%. With a median follow-up time of 34 months after the second transplant, median progression-free survival was 24 months. The median PFS in the patients achieving CR or VGPR at day 100 after the second transplantation was 32 months. By 15 months, all patients achieved only partial remission progressed, with a median PFS of 8.5 months. During the follow-up period, no MDS or AML developed, and the frequency of second malignancy was also low, 3%. In conclusion, second autologous stem cell transplantation is a well-tolerated and effective treatment option for relapsed multiple myeloma in selected patients, though with a shorter PFS than in first remission. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1532-2807 |
| Relation: | https://www.por-journal.com/articles/10.3389/pore.2024.1611851/full; https://doaj.org/toc/1532-2807 |
| DOI: | 10.3389/pore.2024.1611851 |
| URL الوصول: | https://doaj.org/article/187078a22528425e9c5774d1dbdef505 |
| رقم الأكسشن: | edsdoj.187078a22528425e9c5774d1dbdef505 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 15322807 |
|---|---|
| DOI: | 10.3389/pore.2024.1611851 |